Rui Bergantim

Myeloma Elderly Prognostic Score ( MEPS ): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra‐High‐Risk Cytogenetics

Eirini Katodritou, Bruna Ferreira, Efstathios Kastritis, Dimitra Dalampira et autres

Established disease-centered prognostic systems may be less tailored to elderly/non-transplant-eligible (NTE) patients with multiple myeloma (MM), in whom host-related factors such as age, performance status, and renal function strongly influence all-cause outcomes. We developed and evaluated the Myeloma Elderly Prognostic Score (MEPS), …

gr, pt, fi, us (code pays fourni par la source)

Polycythemia, SGLT2 inhibitors, and associated outcomes across the cardio-kidney-metabolic spectrum: a pooled analysis of randomized trials

Pedro Marques, Francisco Vasques-Nóvoa, Mariana Pintalhão, Rui Bergantim et autres

BACKGROUND: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) use increase hemoglobin, and some patients may develop or aggravate polycythemia. Whether the presence or development of polycythemia impact the cardiorenal benefits of SGLT2i across different cardio-kidney-metabolic (CKM) populations is unknown. AIMS: Assess the proportion of …

pt, ca, gr, us, de, fr (code pays fourni par la source)

How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care

Joana Caetano, Ana Marta Pires, Carlos Costa, Rui Bergantim et autres

Multiple myeloma is a complex hematologic malignancy characterized by significant biological heterogeneity, a relapsing-remission clinical course, and a continuously evolving therapeutic landscape. Accurate and timely laboratory assessment is central to disease management, supporting diagnosis, risk stratification, evaluation of treatment response, and long-term …

pt, it, es (code pays fourni par la source)

Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations

Ana Marta Pires, João Pedro Barreto, Joana Caetano, Maria José Soares et autres

Multiple myeloma is a clonal plasma cell malignancy with a highly variable range of clinical manifestations. Over recent decades, substantial progress has been made in laboratory diagnostics, which has deepened our understanding of disease biology, improved risk stratification, and informed treatment strategies. …

pt (code pays fourni par la source)

Darmma – Real Life Experience of the Use of Daratumumab in Multiple Myeloma in Portugal

Manuel Neves, José de Arimatéia Freitas, Adriana Roque, Joana Vieira et autres

Validation of a Simplified Prognostic Score for Transplant-Ineligible Multiple Myeloma Patients in a Portuguese Cohort: A Real-World Analysis Based on the Greek Myeloma Study Group Model - MEPS

Bruna Ferreira, Joana Vieira, Graça Esteves, Helena Martins et autres

Diagnóstico e Seguimento Laboratorial de Doentes com Mieloma Múltiplo: Recomendações do Grupo Português do Mieloma Múltiplo

Ana Marta Pires, João Pedro Barreto, Joana Caetano, Maria José Soares et autres

Multiple myeloma is a neoplasm of plasma cells that in most cases is associated with the secretion of monoclonal immunoglobulins and can involve multiple organs. Its timely diagnosis is essential to limit or avoid irreversible damage and dysfunction of target organs. Appropriate …

pt (code pays fourni par la source)

Challenges in the preclinical design and assessment of CAR-T cells

Radu Tomai, Javier De Las Rivas, Bogdan Fetică, Rui Bergantim et autres

The advent of immunotherapy in the treatment of cancer has opened a new dimension in the management of this complex multifaceted disease, bringing hope to many patients whose tumors have failed to respond to conventional therapies. The adoptive T cell therapy has …

ro, es, pt, rs, ba, de (code pays fourni par la source)

Carfilzomib-Associated Thrombotic Microangiopathy in a Multiple Myeloma Patient: Complement Genetic Alterations Impact and Eculizumab Therapy

Joana Lopes, Vítor Fernandes, Núria Paulo, Pedro Lisboa Gonçalves et autres

Carfilzomib is a second-generation proteasome inhibitor used in relapsed or refractory multiple myeloma (MM). Although effective, it can be associated with rare but life-threatening complications. We describe a 73-year-old woman with relapsed IgG-kappa MM who developed thrombotic microangiopathy (TMA) and acute kidney …

pt (code pays fourni par la source)

MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study

Rui Bergantim, Sara Peixoto da Silva, Vanessa Carla Monteiro Pinto, Joana Pereira et autres

Background Multiple myeloma (MM) is a complex hematological malignancy with heterogeneous clinical and pathophysiological backgrounds that influence treatment responses and outcomes. Identifying biomarkers to predict drug response and guide treatment decisions, particularly regarding drug combinations, is essential to improve therapeutic efficacy and …

pt (code pays fourni par la source)

Elevating fungal care: bridging Brazil’s healthcare practices to global standards

Jon Salmanton‐García, Diego R. Falci, Oliver A. Cornely, Alessandro C. Pasqualotto et autres

Brazil faces unique challenges in managing invasive fungal infections (IFIs) due to diverse ecosystems, a rural workforce, and prevalent health conditions. In Europe, IFIs are primarily associated with transplantation, intensive care, and chronic diseases. Inspired by initiatives in the Caribbean and Latin …

de, us, br, Somalie, ag, fr (code pays fourni par la source)

Clostridium perfringens Sepsis Complicated by Hepatic Abscess Following Intensive Chemotherapy in Mixed-Phenotype Acute Leukemia

Pedro M. Baptista, Marta Henriques, Mariana R. Miranda, Rui Bergantim et autres

Clostridium perfringens (C. perfringens) is a rare cause of febrile neutropenia in patients with acute leukemia, and only a few case reports are published in the literature. The peculiar presentation of this clostridial sepsis, with the formation of gaseous liver abscess and …

pt (code pays fourni par la source)